Valuation: Sight Sciences, Inc.

Market Cap 286M 250M 230M 212M 401M 27.49B 408M 2.75B 1.08B 13.43B 1.07B 1.05B 46.3B P/E 2026 *
-8.23x
P/E 2027 * -10.4x
Enterprise Value 286M 250M 230M 212M 401M 27.49B 408M 2.75B 1.08B 13.43B 1.07B 1.05B 46.3B EV / Sales 2026 *
3.32x
EV / Sales 2027 * 2.99x
Free-Float
80.02%
Yield 2026 *
-
Yield 2027 * -
1 day+3.96%
1 week-1.87%
Current month-3.14%
1 month+4.58%
3 months+34.27%
6 months-20.45%
Current year-33.80%
1 week 5
Extreme 5
5.5
1 month 4.92
Extreme 4.92
5.89
Current year 3.38
Extreme 3.378
8.19
1 year 3.11
Extreme 3.11
9.24
3 years 1.04
Extreme 1.04
9.31
5 years 1.04
Extreme 1.04
42.57
10 years 1.04
Extreme 1.04
42.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 56 2009-12-31
Chief Executive Officer 51 2009-12-31
Director of Finance/CFO 43 2025-11-04
Director TitleAgeSince
Director/Board Member 51 2009-12-31
Director/Board Member 56 2009-12-31
Chairman 74 2016-12-31
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Founder

-7,418 0.0136%
07-05Sell

General Counsel

-12,733 0.0234%
07-01Sell

Chief Operating Officer

-24,184 0.0444%
Change 5-day change 1-year change 3-year change Capi.($)
+3.96%-1.87%+57.19%-32.61% 286M
+1.06%-6.21%-32.11%-17.29% 155B
+1.48%-1.88%-9.81%-8.19% 103B
-1.89%-4.20%+0.65%+54.93% 57.7B
-1.13%+1.09%+37.83%+53.63% 52.27B
+2.81%+2.87%-13.14%-40.29% 42.68B
+2.02%-2.13% - - 33.35B
-1.88%-1.80%-14.21%-47.04% 28.06B
+0.38%+1.50%+62.41%-6.78% 25.36B
+0.27%+9.00%-3.82%-17.97% 21.03B
Average +0.62%+0.02%+9.44%-6.84% 51.92B
Weighted average by Cap. +0.31%-1.71%-7.06%-2.38%

Financials

2026 *2027 *
Net sales 86.03M 75.22M 69.39M 63.78M 121M 8.28B 123M 828M 325M 4.05B 323M 316M 13.95B 95.66M 83.63M 77.15M 70.92M 134M 9.2B 137M 921M 361M 4.5B 359M 351M 15.51B
Net income -34.77M -30.4M -28.05M -25.78M -48.85M -3.35B -49.68M -335M -131M -1.64B -131M -128M -5.64B -28.69M -25.09M -23.14M -21.27M -40.31M -2.76B -41M -276M -108M -1.35B -108M -105M -4.65B
Net Debt - -
Logo Sight Sciences, Inc.
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Employees
186
Date Price Change Volume
26-07-15 US$5.250 +3.96% 128,883
26-07-14 US$5.050 -5.43% 107,207
26-07-13 US$5.340 +0.38% 92,188
26-07-10 US$5.320 +1.14% 123,575
26-07-09 US$5.260 -1.68% 167,529
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.250USD
Average target price
8.750USD
Spread / Average Target
+66.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SGHT Stock